Category: Long Post

Categories
Long Post News

New Milestone Achieved in our Analgesic Program

New Milestone Achieved in our Analgesic Program ”

This month we have completed the first round of optimization for synthesis scaleup of our lead analgesic, Sea4Pain, to a three-step reaction process compatible with GLP and GMP production.

GLP-enabled synthesis of our API was established with adequate purity and solid-state properties, no loss of efficacy and low erosion, excellent conversion and enantiomeric purity.

The produced API will enable the execution of our more advanced GLP preclinical tests.
Sea4Us is now taking forward the CMC work for GMP scaleup, followed by production of lots for the start of clinical trials in Q3 2025.

#Biotechnology #DrugDevelopment #ChronicPain #ScaleUp #ClinicalTrials #Biotecnologia #DesenvolvimentoDeMedicamentos #DorCrónica #EscalaIndustrial #EnsaiosClínicos

Back to News

NEWS
Categories
Long Post News

Taking our non-opioid analgesic to clinical trials: Sea4Market has started

Taking our non-opioid analgesic to clinical trials: Sea4Market has started

Sea4Market is starting, taking our first in class non-opioid analgesic for the treatment of chronic pain to clinical trials in 2025.
Chronic pain affects 1.6 billion people worldwide, which have either ineffective or unsafe treatments available.
Our marine-inspired novel analgesic allows safe and effective treatment, without the associated serious side-effects seen with most available solutions, such as opioids.

Funding through the Accelerator Program from the European Innovation Council and SMEs Executive Agency (EISMEA), Project number 101145231.

Check out our LinkedIn update here.

#Biotechnology #DrugDevelopment #ChronicPain #NonOpioid #EicAccelerator

Back to News

NEWS
Categories
Long Post News

Sea4Us secures Accelerator Program from the EiC and SMEs Executive Agency (EISMEA)

Sea4Us secures Accelerator Program from the EiC and SMEs Executive Agency (EISMEA)

Sea4Us has secured funding through the Accelerator Program from the European Innovation Council and SMEs Executive Agency (EISMEA).

EIC’s support not only showcases Sea4Us’ technological breakthrough but takes us closer to delivering our novel and highly effective analgesic to chronic pain patients. With the 2.5M€ in Grant, from an investment opportunity with EIF (European Investment Fund) of up to 5.96M€ we will change the lives of billions of people worldwide!
The funding received will be crucial in taking our nonopioid treatment to IND and clinical trials.

Chronic pain affects 1.6 billion people worldwide, which have either ineffective or unsafe treatments available.
Our marineinspired novel analgesic will allow for safe and effective treatment, without the associated serious side-effects seen with most available solutions.

We extend our congratulations to PICadvanced and TargTex, who have also achieved great success within the EIC program; and ANI | Agência Nacional de Inovação for the support.

Back to News

NEWS
Categories
Long Post News

Happy to announce our fully renovated Discovery Lab and Headquarters, Sagres

Happy to announce our fully renovated Discovery Lab and Headquarters, Sagres

Our headquarters and Discovery Lab in Sagres has been fully renovated!

After a long and challenging process of plan-making and re-making, we have now a completely new Discovery Lab infrastructure to accommodate our field and sampling work. And fully equipped for our species identification, and where we can bring to light the potential of marine chemistries for human health.

Back to News

NEWS